@article{2a01c9d4fb5a4504b1a23a04b5749d97,
title = "Cortical atrophy and leukoaraiosis, imaging markers of cerebrovascular small vessel disease, are associated with driving behavior changes among cognitively normal older adults",
abstract = "Background: Cerebral small vessel disease (CSVD) as measured by cortical atrophy and white matter hyperintensities [leukoaraiosis], captured via magnetic resonance imaging (MRI) are increasing in prevalence due to the growth of the aging population and an increase in cardiovascular risk factors in the population. CSVD impacts cognitive function and mobility, but it is unclear if it affects complex, functional activities like driving. Methods: In a cohort of 163 cognitively normal, community-dwelling older adults (age ≥ 65), we compared naturalistic driving behavior with mild/moderate leukoaraiosis, cortical atrophy, or their combined rating in a clinical composite termed, aging-related changes to those without any, over a two-and-a-half-year period. Results: Older drivers with mild or moderate cortical atrophy and aging-related changes (composite) experienced a greater decrease in the number of monthly trips which was due to a decrease in the number of trips made within a one-to-five-mile diameter from their residence. Older drivers with CSVD experience a larger reduction in daily driving behaviors than drivers without CSVD, which may serve as an early neurobehavioral marker for functional decline. Conclusions: As CSVD markers, leukoaraiosis and cortical atrophy are standard MRI metrics that are widely available and can be used for screening individuals at higher risk for driving safety risk and decline in community mobility.",
keywords = "Cerebrovascular small vessel disease, Cortical atrophy, Driving, Functional decline, Older adults, White matter hyperintensities",
author = "Babulal, {Ganesh M.} and Ling Chen and Carr, {David B.} and Johnson, {Ann M.} and Shimony, {Joshua S.} and Jason Doherty and Samantha Murphy and Alexis Walker and Hailee Domash and Russ Hornbeck and Sarah Keefe and Shaney Flores and Raji, {Cyrus A.} and Morris, {John C.} and Ances, {Beau M.} and Benzinger, {Tammie L.S.}",
note = "Funding Information: This work was funded by the National Institute of Health (NIH) and National Institute on Aging (NIH/NIA) grants R01AG056466 (GMB), R01AG068183 (GMB), R01AG067428 (GMB), P30 AG066444 (JCM), P01AG03991 (JCM/TB/BA), P01AG26276 ) (JCM/TB). This work was also supported by the BrightFocus Foundation A2021142S (GMB). The authors thank the participants, investigators/staff of the Knight ADRC Clinical and Imaging Cores. Funding Information: Dr. Raji, unrelated to this work, has had investigator-initiated research funding from the NIH, the Radiological Society of North America, and the American Society of Neuroradiology. Dr. Raji also performs paid consulting for Brainreader, Neurevolution, Apollo Health, Icometrix, and the Pacific Neuroscience Foundation. Unrelated to this work, Dr. Benzinger has had investigator-initiated research funding from the NIH, the Alzheimer's Association, the Barnes-Jewish Hospital Foundation, Siemens Healthineers and Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly). Dr. Benzinger participates as a site investigator in clinical trials sponsored by Avid Radiopharmaceuticals, Eli Lilly, Biogen, Eisai, Jaansen, and Roche. Dr. Benzinger performs paid and unpaid consulting for Biogen, Eli Lilly, Eisai, and Siemens.This work was funded by the National Institute of Health (NIH) and National Institute on Aging (NIH/NIA) grants R01AG056466 (GMB), R01AG068183 (GMB), R01AG067428 (GMB), P30 AG066444 (JCM), P01AG03991(JCM/TB/BA), P01AG26276) (JCM/TB). This work was also supported by the BrightFocus Foundation A2021142S (GMB). The authors thank the participants, investigators/staff of the Knight ADRC Clinical and Imaging Cores. Funding Information: Dr. Raji, unrelated to this work, has had investigator-initiated research funding from the NIH, the Radiological Society of North America, and the American Society of Neuroradiology. Dr. Raji also performs paid consulting for Brainreader, Neurevolution, Apollo Health, Icometrix, and the Pacific Neuroscience Foundation. Unrelated to this work, Dr. Benzinger has had investigator-initiated research funding from the NIH, the Alzheimer's Association, the Barnes-Jewish Hospital Foundation, Siemens Healthineers and Avid Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly). Dr. Benzinger participates as a site investigator in clinical trials sponsored by Avid Radiopharmaceuticals , Eli Lilly, Biogen, Eisai, Jaansen, and Roche. Dr. Benzinger performs paid and unpaid consulting for Biogen, Eli Lilly, Eisai, and Siemens. Publisher Copyright: {\textcopyright} 2023 The Authors",
year = "2023",
month = may,
day = "15",
doi = "10.1016/j.jns.2023.120616",
language = "English",
volume = "448",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
}